<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01545141</url>
  </required_header>
  <id_info>
    <org_study_id>10-131</org_study_id>
    <secondary_id>10-131</secondary_id>
    <nct_id>NCT01545141</nct_id>
  </id_info>
  <brief_title>Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer</brief_title>
  <official_title>Randomized Phase 1/2 Evaluation of Neoadjuvant Administration of a Chemokine-Modulatory Regimen in Patients With Recurrent Resectable Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roswell Park Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AIM ImmunoTech Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Roswell Park Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Determine the safety of a combination of IFN, celecoxib, and rintatolimod for patients with&#xD;
      recurrent colorectal cancer. This will also test whether the above combination can help the&#xD;
      immune system to fight the tumors. The results will allow the investigators to determine the&#xD;
      &quot;preferred&quot; combination for subsequent extended studies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A previously-demonstrated correlation between the density of CRC-infiltrating effector T&#xD;
      cells and long-term outcomes (Galon et al., 2006; Pages et al., 2005) has been established.&#xD;
      In preclinical ex vivo studies performed using explants of resected metastatic CRC, the&#xD;
      combination of IFNα with nonselective or COX2-selective inhibitors of prostaglandin synthesis&#xD;
      resulted in elevated production of the effector T cell-attracting chemokines CXCL10 and CCL5.&#xD;
      This was associated with concomitant suppression of the intratumoral expression of CCL22, a&#xD;
      Treg-attracting chemokine (Muthuswamy et al 2008 Canc Res, and Muthuswamy et al, submitted to&#xD;
      Canc Res 2011). However, in a subset of patients, the optimal results, particularly with&#xD;
      regard to CCL5 induction, required additional stimulation by a third agent, poly-I:C (a&#xD;
      toll-like receptor -TLR Ligand).&#xD;
&#xD;
      Therefore, the investigators seek to establish the safety profile of a novel chemokine&#xD;
      regimen consisting of IFN, celecoxib and poly-I:C. The investigators also hypothesize that&#xD;
      the proposed neoadjuvant chemokine modulation treatment in recurrent CRC patients undergoing&#xD;
      tumor resection may increase the density of tumor infiltrating lymphocytes (TILS).&#xD;
&#xD;
      In addition, treatment in the neoadjuvant setting will allow a comparative analysis of the&#xD;
      effect of chemokine modulation on the local recruitment of effector-type T cells and the&#xD;
      de-recruitment of Treg within resected tumor tissues; helping to determine the &quot;preferred&quot;&#xD;
      chemokine-modulating regimen for subsequent extended studies. Such prospective studies will&#xD;
      focus on using combinations of chemokine modulation and cancer vaccines in patients with CRC.&#xD;
      The investigators have, for example, recently observed that αDC1, a new type of DC vaccine&#xD;
      (Kalinski and Okada, 2010; Mailliard et al., 2004) is particularly effective in inducing the&#xD;
      effector pathway of T cells differentiation. This was manifested by the induction of&#xD;
      tumor-killing function and the induction of effector-type chemokine receptors (CXCR3 and&#xD;
      CCR5) (Kalinski and Okada, 2010; Watchmaker et al., 2010). Combining the αDC1 vaccine to a&#xD;
      safe, tolerable and efficacious CKM regimen may hold promise for patients with poor&#xD;
      prognostic CRC.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">April 8, 2017</completion_date>
  <primary_completion_date type="Actual">April 8, 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the Number of Tumor-infiltrating CD8+ Cells.</measure>
    <time_frame>Day of surgery: day 8-10</time_frame>
    <description>This will be assessed by the increase in the total number of tumor-infiltrating CD8+ T cells in the resected, recurrent CRC lesions (measured as the ratio between the CD8 mRNA message and the expression of the housekeeping gene HPRT), comparing Arm A and Arm B.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment Related Adverse Events</measure>
    <time_frame>1 week</time_frame>
    <description>The number of adverse events experienced within 1 week of treatment. This was completed for the Phase II portion of the study.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Colorectal Carcinoma</condition>
  <condition>Colorectal Tumors</condition>
  <condition>Neoplasms, Colorectal</condition>
  <arm_group>
    <arm_group_label>Surgery only</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Surgical resection only, performed as standard of care for the disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemokin Modulatory Regimen (5 MU/m2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chemokine Modulatory Regimen monday through Friday prior to surgery:&#xD;
400 mg celecoxib for 5 days IFN by intravenous infusion (IV) (Phase 1 dose escalation of 5 MU/m2) for 5 days Rintatolimod 200 mg by IV infusion for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemokin Modulatory Regimen (10 MU/m2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chemokine Modulatory Regimen monday through Friday prior to surgery:&#xD;
400 mg celecoxib for 5 days IFN by intravenous infusion (IV) (Phase 1 dose escalation of 10 MU/m2) for 5 days Rintatolimod 200 mg by IV infusion for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemokin Modulatory Regimen (20 MU/m2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chemokine Modulatory Regimen monday through Friday prior to surgery:&#xD;
400 mg celecoxib for 5 days IFN by intravenous infusion (IV) (Phase 1 dose escalation of 20 MU/m2) for 5 days Rintatolimod 200 mg by IV infusion for 5 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemokin Modulatory Regimen (5 MU/m2)</intervention_name>
    <description>Celecoxib: 200 mg twice/day M-F of the week prior to scheduled surgery rintatolimod: 200 mg i.v. administration M-F of the week prior to scheduled surgery IFN: i.v. administration, M-F of the week prior to scheduled surgery. Dose escalation evaluating 5, 10, and 20 MU/m2.</description>
    <arm_group_label>Chemokin Modulatory Regimen (5 MU/m2)</arm_group_label>
    <other_name>Celebrex</other_name>
    <other_name>INTRON A</other_name>
    <other_name>Interferon-alpha 2b</other_name>
    <other_name>IFN-alpha</other_name>
    <other_name>Ampligen</other_name>
    <other_name>rintatolimod</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemokin Modulatory Regimen (10 MU/m2)</intervention_name>
    <description>Celecoxib: 200 mg twice/day M-F of the week prior to scheduled surgery rintatolimod: 200 mg i.v. administration M-F of the week prior to scheduled surgery</description>
    <arm_group_label>Chemokin Modulatory Regimen (10 MU/m2)</arm_group_label>
    <other_name>Celebrex</other_name>
    <other_name>INTRON A</other_name>
    <other_name>Interferon-alpha 2b</other_name>
    <other_name>IFN-alpha</other_name>
    <other_name>Ampligen</other_name>
    <other_name>rintatolimod</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemokin Modulatory Regimen (20 MU/m2)</intervention_name>
    <description>Celecoxib: 200 mg twice/day M-F of the week prior to scheduled surgery rintatolimod: 200 mg i.v. administration M-F of the week prior to scheduled surgery</description>
    <arm_group_label>Chemokin Modulatory Regimen (20 MU/m2)</arm_group_label>
    <other_name>Celebrex</other_name>
    <other_name>INTRON A</other_name>
    <other_name>Interferon-alpha 2b</other_name>
    <other_name>IFN-alpha</other_name>
    <other_name>Ampligen</other_name>
    <other_name>rintatolimod</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion:&#xD;
&#xD;
          -  Recurrent and/or metastatic resectable colorectal cancer, including disease within the&#xD;
             abdomen and pelvis with no evidence of extra-abdominal metastases. Isolated resectable&#xD;
             pulmonary metastasis are allowable in the absence of intra-abdominal metastasis.&#xD;
             Intra-abdominal disease includes: isolated hepatic metastasis/metastases (see next&#xD;
             inclusion criteria point), isolated peritoneal metastasis, peritoneal carcinomatosis&#xD;
             (including patients undergoing cytoreductive surgery alone or in combination with&#xD;
             hyperthermic intraperitoneal chemoperfusion - HIPEC), or a combination of hepatic and&#xD;
             extrahepatic metastasis.&#xD;
&#xD;
          -  Patients with isolated hepatic metastasis must satisfy a Clinical Risk Score of 3 or&#xD;
             higher (see Appendix C)&#xD;
&#xD;
          -  Eligible patients are expected to have a complete resection based on preoperative&#xD;
             imaging. Any patient not found to be able to have complete resection will not be&#xD;
             eligible for this study.&#xD;
&#xD;
          -  No chemotherapy, radiotherapy, major surgery, or biologic therapy within 3 weeks of&#xD;
             protocol treatment&#xD;
&#xD;
          -  An ECOG performance status of 0, 1, or 2.&#xD;
&#xD;
          -  Age equal to 18 years or older.&#xD;
&#xD;
          -  Must have normal organ and marrow function as defined below:&#xD;
&#xD;
               -  Platelet ≥ 75,000/µL&#xD;
&#xD;
               -  Hemoglobin ≥ 9.0 g/dL&#xD;
&#xD;
               -  Hematocrit ≥ 27.0%&#xD;
&#xD;
               -  Absolute Neutrophil Count (ANC) ≥ 1500/µL&#xD;
&#xD;
               -  Creatinine &lt; institutional upper limit of normal (ULN) OR&#xD;
&#xD;
               -  Creatinine clearance ≥ 50 mL/min/1.73 m2 for patients with creatinine levels&#xD;
                  greater than ULN&#xD;
&#xD;
               -  Total bilirubin ≤ 1.5 X institutional upper limit of normal (ULN)&#xD;
&#xD;
               -  AST(SGOT) and ALT(SGPT) ≤ 2.5 X institutional upper limit of normal (ULN)&#xD;
&#xD;
               -  Serum amylase and lipase within normal limits.&#xD;
&#xD;
          -  Patient must be able to understand and be willing to sign a written informed consent&#xD;
             document.&#xD;
&#xD;
        Exclusion:&#xD;
&#xD;
          -  Patients currently treated with systemic immunosuppressive agents, including steroids,&#xD;
             are ineligible until 3 weeks after removal from immunosuppressive treatment.&#xD;
&#xD;
          -  Patients with active autoimmune disease or history of transplantation.&#xD;
&#xD;
          -  Patients who are pregnant or nursing. Women of childbearing potential (WOCBP) will&#xD;
             have to undergo a urine pregnancy test as part of screening.&#xD;
&#xD;
          -  Patients with comorbid medical conditions that render them unfit for surgery.&#xD;
&#xD;
          -  Metastatic or recurrent disease that is deemed partially resectable or unresectable&#xD;
             based on preoperative imaging.&#xD;
&#xD;
          -  Metastatic disease outside the confines of the abdomen, pelvis and thorax (e.g bone,&#xD;
             brain)&#xD;
&#xD;
          -  Cardiac risk factors including:&#xD;
&#xD;
               -  Patients experiencing cardiac event(s) (acute coronary syndrome, myocardial&#xD;
                  infarction, or ischemia) within 3 months of signing consent&#xD;
&#xD;
               -  Patients with a New York Heart Association classification of III or IV (Appendix&#xD;
                  A)&#xD;
&#xD;
          -  History of upper gastrointestinal ulceration, upper gastrointestinal bleeding, or&#xD;
             upper gastrointestinal perforation within the past 3 years. Patients with ulceration,&#xD;
             bleeding or perforation in the lower bowel are not excluded.&#xD;
&#xD;
          -  Prior allergic reaction or hypersensitivity to sulfonamides, celecoxib, or NSAIDs.&#xD;
&#xD;
          -  Patients are ineligible if they plan on regular use of NSAIDs at any dose more than 2&#xD;
             times per week (on average) or aspirin at more than 325 mg at least three times per&#xD;
             week, on average. Low-dose aspirin not exceeding 100 mg/day is permitted. Patients who&#xD;
             agree to stop regular NSAIDs or higher dose aspirin are eligible and no wash out&#xD;
             period is required.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amer H Zureikat, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UPMC Hillman Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>February 29, 2012</study_first_submitted>
  <study_first_submitted_qc>February 29, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2012</study_first_posted>
  <results_first_submitted>July 14, 2020</results_first_submitted>
  <results_first_submitted_qc>August 21, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 9, 2020</results_first_posted>
  <last_update_submitted>August 21, 2020</last_update_submitted>
  <last_update_submitted_qc>August 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>metastatic</keyword>
  <keyword>recurrent</keyword>
  <keyword>peritoneal metastasis</keyword>
  <keyword>cytoreductive surgery</keyword>
  <keyword>hyperthermic intraperitoneal chemoperfusion</keyword>
  <keyword>HIPEC</keyword>
  <keyword>hepatic metastasis</keyword>
  <keyword>extrahepatic metastasis</keyword>
  <keyword>vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Interferon alpha-2</mesh_term>
    <mesh_term>Interferon-alfa-1b</mesh_term>
    <mesh_term>poly(I).poly(c12,U)</mesh_term>
    <mesh_term>Poly I-C</mesh_term>
    <mesh_term>Celecoxib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>9 Patients were enrolled in Phase I. 6 Patients were enrolled in Phase II prior to study termination (funding).</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Surgery Only</title>
          <description>Surgical resection only, performed as standard of care for the disease</description>
        </group>
        <group group_id="P2">
          <title>Chemokin Modulatory Regimen (5 MU/m2)</title>
          <description>Chemokine Modulatory Regimen monday through Friday prior to surgery:&#xD;
400 mg celecoxib for 5 days IFN by intravenous infusion (IV) (Phase 1 dose escalation of 5, 10, and 20 MU/m2) for 5 days Rintatolimod 200 mg by IV infusion for 5 days&#xD;
Chemokine modulatory regimen: Celecoxib: 200 mg twice/day M-F of the week prior to scheduled surgery rintatolimod: 200 mg i.v. administration M-F of the week prior to scheduled surgery IFN: i.v. administration, M-F of the week prior to scheduled surgery. Dose escalation evaluating 5, 10, and 20 MU/m2.</description>
        </group>
        <group group_id="P3">
          <title>Chemokin Modulatory Regimen (10 MU/m2)</title>
          <description>Chemokine Modulatory Regimen monday through Friday prior to surgery:&#xD;
400 mg celecoxib for 5 days IFN by intravenous infusion (IV) (Phase 1 dose escalation of 5 MU/m2) for 5 days Rintatolimod 200 mg by IV infusion for 5 days</description>
        </group>
        <group group_id="P4">
          <title>Chemokin Modulatory Regimen (20 MU/m2)</title>
          <description>Chemokine Modulatory Regimen monday through Friday prior to surgery:&#xD;
400 mg celecoxib for 5 days IFN by intravenous infusion (IV) (Phase 1 dose escalation of 20 MU/m2) for 5 days Rintatolimod 200 mg by IV infusion for 5 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>9 patients in Phase I 6 patients in Phase II</population>
      <group_list>
        <group group_id="B1">
          <title>Surgery Only</title>
          <description>Surgical resection only, performed as standard of care for the disease</description>
        </group>
        <group group_id="B2">
          <title>Chemokine Modulatory Regimen (5 MU/m2)</title>
          <description>Chemokine Modulatory Regimen monday through Friday prior to surgery:&#xD;
400 mg celecoxib for 5 days IFN by intravenous infusion (IV) (Phase 1 dose escalation of 5, 10, and 20 MU/m2) for 5 days Rintatolimod 200 mg by IV infusion for 5 days&#xD;
Chemokine modulatory regimen: Celecoxib: 200 mg twice/day M-F of the week prior to scheduled surgery rintatolimod: 200 mg i.v. administration M-F of the week prior to scheduled surgery IFN: i.v. administration, M-F of the week prior to scheduled surgery. Dose escalation evaluating 5, 10, and 20 MU/m2.</description>
        </group>
        <group group_id="B3">
          <title>Chemokine Modulatory Regimen (10 MU/m2)</title>
          <description>Chemokine Modulatory Regimen monday through Friday prior to surgery:&#xD;
400 mg celecoxib for 5 days IFN by intravenous infusion (IV) (Phase 1 dose escalation of 5, 10, and 20 MU/m2) for 5 days Rintatolimod 200 mg by IV infusion for 5 days&#xD;
Chemokine modulatory regimen: Celecoxib: 200 mg twice/day M-F of the week prior to scheduled surgery rintatolimod: 200 mg i.v. administration M-F of the week prior to scheduled surgery IFN: i.v. administration, M-F of the week prior to scheduled surgery. Dose escalation evaluating 5, 10, and 20 MU/m2.</description>
        </group>
        <group group_id="B4">
          <title>Chemokine Modulatory Regimen (20 MU/m2)</title>
          <description>Chemokine Modulatory Regimen monday through Friday prior to surgery:&#xD;
400 mg celecoxib for 5 days IFN by intravenous infusion (IV) (Phase 1 dose escalation of 5, 10, and 20 MU/m2) for 5 days Rintatolimod 200 mg by IV infusion for 5 days&#xD;
Chemokine modulatory regimen: Celecoxib: 200 mg twice/day M-F of the week prior to scheduled surgery rintatolimod: 200 mg i.v. administration M-F of the week prior to scheduled surgery IFN: i.v. administration, M-F of the week prior to scheduled surgery. Dose escalation evaluating 5, 10, and 20 MU/m2.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="3"/>
            <count group_id="B4" value="7"/>
            <count group_id="B5" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.0" spread="4.2"/>
                    <measurement group_id="B2" value="62.7" spread="13.7"/>
                    <measurement group_id="B3" value="60.0" spread="15.9"/>
                    <measurement group_id="B4" value="47.1" spread="15.3"/>
                    <measurement group_id="B5" value="55.1" spread="15.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in the Number of Tumor-infiltrating CD8+ Cells.</title>
        <description>This will be assessed by the increase in the total number of tumor-infiltrating CD8+ T cells in the resected, recurrent CRC lesions (measured as the ratio between the CD8 mRNA message and the expression of the housekeeping gene HPRT), comparing Arm A and Arm B.</description>
        <time_frame>Day of surgery: day 8-10</time_frame>
        <population>The study was terminated prior to completion of enrollment for Phase II and the T-cell analysis was not completed.</population>
        <group_list>
          <group group_id="O1">
            <title>Surgery Only</title>
            <description>Surgical resection only, performed as standard of care for the disease</description>
          </group>
          <group group_id="O2">
            <title>Chemokin Modulatory Regimen Prior to Surgery (20 MU/m2)</title>
            <description>Chemokine Modulatory Regimen monday through Friday prior to surgery:&#xD;
400 mg celecoxib for 5 days IFN by intravenous infusion (IV) (Phase 2 dose of and 20 MU/m2) for 5 days Rintatolimod 200 mg by IV infusion for 5 days&#xD;
Chemokine modulatory regimen: Celecoxib: 200 mg twice/day M-F of the week prior to scheduled surgery rintatolimod: 200 mg i.v. administration M-F of the week prior to scheduled surgery IFN: i.v. administration, M-F of the week prior to scheduled surgery. Dose escalation evaluating 5, 10, and 20 MU/m2.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Number of Tumor-infiltrating CD8+ Cells.</title>
          <description>This will be assessed by the increase in the total number of tumor-infiltrating CD8+ T cells in the resected, recurrent CRC lesions (measured as the ratio between the CD8 mRNA message and the expression of the housekeeping gene HPRT), comparing Arm A and Arm B.</description>
          <population>The study was terminated prior to completion of enrollment for Phase II and the T-cell analysis was not completed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Related Adverse Events</title>
        <description>The number of adverse events experienced within 1 week of treatment. This was completed for the Phase II portion of the study.</description>
        <time_frame>1 week</time_frame>
        <population>The study was terminated prior to completion of enrollment for Phase II. The Phase II portion of the study involved Surgery alone and Chemokin Modulatory Regimen prior to surgery at 20 MU/m2.</population>
        <group_list>
          <group group_id="O1">
            <title>Surgery Only</title>
            <description>Surgical resection only, performed as standard of care for the disease</description>
          </group>
          <group group_id="O2">
            <title>Chemokin Modulatory Regimen Prior to Surgery (20 MU/m2)</title>
            <description>Chemokine Modulatory Regimen monday through Friday prior to surgery:&#xD;
400 mg celecoxib for 5 days IFN by intravenous infusion (IV) (Phase 2 dose of 20 MU/m2) for 5 days Rintatolimod 200 mg by IV infusion for 5 days&#xD;
Chemokine modulatory regimen: Celecoxib: 200 mg twice/day M-F of the week prior to scheduled surgery rintatolimod: 200 mg i.v. administration M-F of the week prior to scheduled surgery IFN: i.v. administration, M-F of the week prior to scheduled surgery. Dose escalation evaluating 5, 10, and 20 MU/m2.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Related Adverse Events</title>
          <description>The number of adverse events experienced within 1 week of treatment. This was completed for the Phase II portion of the study.</description>
          <population>The study was terminated prior to completion of enrollment for Phase II. The Phase II portion of the study involved Surgery alone and Chemokin Modulatory Regimen prior to surgery at 20 MU/m2.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The adverse events were measured for 30 days after treatment.</time_frame>
      <desc>Definitions are as described in clinicaltrials.gov</desc>
      <group_list>
        <group group_id="E1">
          <title>Surgery Only</title>
          <description>Surgical resection only, performed as standard of care for the disease</description>
        </group>
        <group group_id="E2">
          <title>Chemokin Modulatory Regimen Prior to Surgery (5 MU/m2)</title>
          <description>Chemokine Modulatory Regimen monday through Friday prior to surgery:&#xD;
400 mg celecoxib for 5 days IFN by intravenous infusion (IV) (Phase 1 dose escalation of 5, 10, and 20 MU/m2) for 5 days Rintatolimod 200 mg by IV infusion for 5 days&#xD;
Chemokine modulatory regimen: Celecoxib: 200 mg twice/day M-F of the week prior to scheduled surgery rintatolimod: 200 mg i.v. administration M-F of the week prior to scheduled surgery IFN: i.v. administration, M-F of the week prior to scheduled surgery. Dose escalation evaluating 5, 10, and 20 MU/m2.</description>
        </group>
        <group group_id="E3">
          <title>Chemokin Modulatory Regimen Prior to Surgery (10 MU/m2)</title>
          <description>Chemokine Modulatory Regimen monday through Friday prior to surgery:&#xD;
400 mg celecoxib for 5 days IFN by intravenous infusion (IV) (Phase 1 dose escalation of 5, 10, and 20 MU/m2) for 5 days Rintatolimod 200 mg by IV infusion for 5 days&#xD;
Chemokine modulatory regimen: Celecoxib: 200 mg twice/day M-F of the week prior to scheduled surgery rintatolimod: 200 mg i.v. administration M-F of the week prior to scheduled surgery IFN: i.v. administration, M-F of the week prior to scheduled surgery. Dose escalation evaluating 5, 10, and 20 MU/m2.</description>
        </group>
        <group group_id="E4">
          <title>Chemokin Modulatory Regimen Prior to Surgery (20 MU/m2)</title>
          <description>Chemokine Modulatory Regimen monday through Friday prior to surgery:&#xD;
400 mg celecoxib for 5 days IFN by intravenous infusion (IV) (Phase 1 dose escalation of 5, 10, and 20 MU/m2) for 5 days Rintatolimod 200 mg by IV infusion for 5 days&#xD;
Chemokine modulatory regimen: Celecoxib: 200 mg twice/day M-F of the week prior to scheduled surgery rintatolimod: 200 mg i.v. administration M-F of the week prior to scheduled surgery IFN: i.v. administration, M-F of the week prior to scheduled surgery. Dose escalation evaluating 5, 10, and 20 MU/m2.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <description>Grade 4</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="6" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastroesophageal reflux disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Flu like symptoms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Serum amylase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kris Attwood</name_or_title>
      <organization>Roswell Park Cancer Institute</organization>
      <phone>716-845-2300</phone>
      <email>Kristopher.attwood@roswellpark.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

